<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00219739</url>
  </required_header>
  <id_info>
    <org_study_id>SPIRIT</org_study_id>
    <nct_id>NCT00219739</nct_id>
  </id_info>
  <brief_title>STI571 ProspectIve RandomIzed Trial: SPIRIT</brief_title>
  <acronym>SPIRIT</acronym>
  <official_title>A Phase III Prospective Randomized Comparison of Imatinib at a Dose of 400mg in Combination With Peg-Interferon-alpha2a (Peg-IFNa2a) or Cytarabine (Ara-C)Versus Imatinib at a Dose of 600mg Versus Imatinib a Dose of 400mg for Previously Untreated Chronic Myelogenous Leukemia (CML) in Chronic Phase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <brief_summary>
    <textblock>
      To test whether increasing the dose of imatinib or combining it with IFNalpha or ara-C
      increases the rate of molecular response (as measured by the decrease in BCR-ABL transcripts
      after 12 months of treatment) in patients with previously untreated CML in chronic phase.

      To compare overall survival in a selected arm according to molecular response at 1 year from
      randomization with the reference arm.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Imatinib at 400 mg daily has emerged as the preferred therapy for newly diagnosed CML
      patients who do not undergo allogeneic stem cell transplant.

      A phase III randomized study, comparing imatinib at 400 mg per day to interferon plus
      cytarabine in newly diagnosed chronic phase CML patients enrolled 1106 patients from June
      2000 to January 2001. 553 patients were randomized to each treatment. For comparative
      purposes, at 6 months, 75% of patients randomized to imatinib obtained a major cytogenetic
      response with 51% complete responses. Despite these impressive results, only a minority of
      patients treated with imatinib in this study achieved a molecular remission. When analyzed by
      log reduction in Bcr-Abl transcript levels using quantitative RT-PCR, 39% of patients
      achieved a 3-log reduction in Bcr-Abl levels, but only 13% and 3% achieved a 4- and 5-log
      reduction, respectively.2 To improve upon these results, various groups have tried higher
      doses of imatinib, and combinations of imatinib with interferon alpha or cytarabine. Each of
      these studies has used cytogenetic responses as the major endpoint.

      Each of these therapies has increased toxicity as compared to 400 mg of imatinib alone and
      the rates of molecular remissions have not been reported.

      Thus the purpose of this study is to first determine whether higher doses of imatinib or
      combining Imatinib with interferon or Ara-C would result in higher rates of molecular
      responses and if so, in better survival.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival improvement</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Molecular response improvement at 1 year</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematological, cytogenetic responses improvement</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of responses improvement</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival without progression improvement</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptable toxicity</measure>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">789</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Imatinib mesylate 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Imatinib mesylate 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Imatinib mesylate 400 mg +Peg interferon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Imatinib mesylate 400 mg +Cytarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib mesylate 400 mg</intervention_name>
    <arm_group_label>Imatinib mesylate 400 mg</arm_group_label>
    <arm_group_label>Imatinib mesylate 600 mg</arm_group_label>
    <arm_group_label>Imatinib mesylate 400 mg +Peg interferon</arm_group_label>
    <arm_group_label>Imatinib mesylate 400 mg +Cytarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib mesylate 600 mg</intervention_name>
    <arm_group_label>Imatinib mesylate 400 mg</arm_group_label>
    <arm_group_label>Imatinib mesylate 600 mg</arm_group_label>
    <arm_group_label>Imatinib mesylate 400 mg +Peg interferon</arm_group_label>
    <arm_group_label>Imatinib mesylate 400 mg +Cytarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib 400 mg + Peg-Interferon</intervention_name>
    <arm_group_label>Imatinib mesylate 400 mg</arm_group_label>
    <arm_group_label>Imatinib mesylate 600 mg</arm_group_label>
    <arm_group_label>Imatinib mesylate 400 mg +Peg interferon</arm_group_label>
    <arm_group_label>Imatinib mesylate 400 mg +Cytarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib mesylate 400 mg + Cytarabine</intervention_name>
    <arm_group_label>Imatinib mesylate 400 mg</arm_group_label>
    <arm_group_label>Imatinib mesylate 600 mg</arm_group_label>
    <arm_group_label>Imatinib mesylate 400 mg +Peg interferon</arm_group_label>
    <arm_group_label>Imatinib mesylate 400 mg +Cytarabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 18 years of age

          -  Patients with Bcr-Abl positive CML in chronic phase.

          -  Patients within 14 weeks of diagnosis and previously untreated for CML except for
             hydroxyurea and/or anagrelide.

          -  No evidence of extramedullary leukemic involvement, with the exception of
             hepatosplenomegaly

          -  ECOG performance score of 0-2

          -  acceptable hepatic, renal, and cardiac function

          -  Informed consent signed up

        Exclusion Criteria:

          -  Depressive syndrome not controlled

          -  Uncontrolled medical illnesses.

          -  Women with childbearing potential and male patients who are unwilling or unable to use
             an adequate method to avoid pregancy for the entire period of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fran√ßois GUILHOT, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Oncology hematology and Cell therapy, University Hospital , 86021 Poitiers - FRANCE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://lmc-cml.org/fr/</url>
    <description>French CML Group (FI-LMC) web-site</description>
  </link>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>October 10, 2016</last_update_submitted>
  <last_update_submitted_qc>October 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CML</keyword>
  <keyword>Imatinib</keyword>
  <keyword>Interferon</keyword>
  <keyword>Cytarabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

